BioNTech SEBNTX -0.81%62 Return-on-Tangible-Equity is -12.42% as of Mar. 2026. GuruFocus rates BNTX with a GF Score™ of 62/100 and a GF Value™ of $87.45 (Fairly Valued). The stock has 5 warning signs investors should review. Among 1,195 Biotechnology companies, BioNTech SE ranks better than 72.05% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. BioNTech SE's annualized net income for the quarter that ended in Mar. 2026 was $-2,460 Mil. BioNTech SE's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $19,799 Mil. Therefore, BioNTech SE's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -12.42%.
The historical rank and industry rank for BioNTech SE's Return-on-Tangible-Equity or its related term are showing as below:
BNTX'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -240.49 Med: -0.78 Max: 158.44
Current: -7.49
During the past 10 years, BioNTech SE's highest Return-on-Tangible-Equity was 158.44%. The lowest was -240.49%. And the median was -0.78%.
BNTX's Return-on-Tangible-Equity is ranked better than 72.05% of 1195
companies
in the Biotechnology industry
Industry Median: -42.21
vs BNTX: -7.49
BioNTech SE (NAS:BNTX) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
BioNTech SE Return-on-Tangible-Equity Related Terms
BioNTech SE Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for BioNTech SE's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BNTX vs INCY, INSM, ROIV: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, BioNTech SE's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioNTech SE Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioNTech SE's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where BioNTech SE's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -12.42% mean?
BioNTech SE (BNTX) has a Return-on-Tangible-Equity of -12.42% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BioNTech SE and its competitors. According to the industry distribution chart, BioNTech SE ranks #334 out of 1195 companies in the Biotechnology industry, placing it in the top 27.9%.
Is BioNTech SE's Return-on-Tangible-Equity too high?
BioNTech SE's current Return-on-Tangible-Equity is -12.42%. Based on the distribution chart, BioNTech SE ranks #334 out of 1195 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioNTech SE has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Return-on-Tangible-Equity compare to INCY and INSM?
According to the Biotechnology industry distribution chart, BioNTech SE ranks #334 out of 1195 companies for Return-on-Tangible-Equity. This puts BioNTech SE in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on BioNTech SE and its competitors. BioNTech SE's current Return-on-Tangible-Equity is -12.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
Based on GuruFocus' analysis, BioNTech SE (BNTX) is currently considered Fairly Valued. The stock's GF Value™ is $87.45, compared to a current price of $93.53 — trading 7% above its estimated fair value. The current Return-on-Tangible-Equity is -12.42%. BioNTech SE's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For BioNTech SE (BNTX), the current Return-on-Tangible-Equity is -12.42% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioNTech SE (BNTX) Overvalued in 2026?
Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued.
The current stock price of $93.53 is trading 7% above its estimated GF Value™ of $87.45.
GuruFocus considers BioNTech SE to be Fairly Valued.
Key valuation signals for BNTX:
Return-on-Tangible-Equity: -12.42%
GF Value™: $87.45 vs. price of $93.53 (7% above fair value)
No single metric tells the full story. See the BNTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
62GF Score
Get the complete analysis for BNTX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNTX has been successfully added to your 
